Kazia Therapeutics (NASDAQ:KZIA) Lowered to “Hold” at Maxim Group

Maxim Group downgraded shares of Kazia Therapeutics (NASDAQ:KZIAGet Rating) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning, The Fly reports.

Separately, HC Wainwright lowered Kazia Therapeutics from a buy rating to a neutral rating in a research note on Tuesday.

Kazia Therapeutics Trading Up 4.8 %

KZIA stock opened at $1.86 on Tuesday. The business’s fifty day simple moving average is $4.29 and its two-hundred day simple moving average is $5.95. Kazia Therapeutics has a twelve month low of $1.63 and a twelve month high of $12.28.

Hedge Funds Weigh In On Kazia Therapeutics

A hedge fund recently bought a new stake in Kazia Therapeutics stock. Envestnet Asset Management Inc. purchased a new stake in shares of Kazia Therapeutics Limited (NASDAQ:KZIAGet Rating) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 26,412 shares of the company’s stock, valued at approximately $223,000. Envestnet Asset Management Inc. owned 0.20% of Kazia Therapeutics at the end of the most recent quarter. Institutional investors own 3.60% of the company’s stock.

About Kazia Therapeutics

(Get Rating)

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer.

Read More

The Fly logo

Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.